ARTICLE | Clinical News
House dust mite (HDM) sublingual allergy immunotherapy (SLIT) regulatory update
March 10, 2017 7:39 PM UTC
FDA approved a BLA for ALK-Abello’s HDM SLIT to treat HDM-induced rhinitis with or without conjunctivitis. ALK-Abello said the launch of the immunotherapy is “likely looking towards 2018.” Last year, ...
BCIQ Company Profiles